Session Type: ACR Late-breaking Abstract Session
Session Time: 9:00AM-11:00AM
Background/Purpose: Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies we have proven the significance of an acquired IL-2 deficiency and related Treg defects in the pathogenesis of systemic lupus erythematosus (SLE). Accordingly, we showed that compensation of IL-2 deficiency by low dose IL-2 therapy is capable to correct Treg defects in SLE patients.
Methods: 10 patients with active and refractory SLE (SLEDAI ≥ 6; at least two different immunosuppressive therapies) were enroled into the trial and 2 patients were treated „off-label“ with the same regimen. The therapeutic regimen consisted of four treatment cycles each with daily subcutaneous injections of recombinant human IL-2 (aldesleukin) at single doses of 0.75, 1.5 or 3.0 million IU on five consecutive days separated by washout-periods of 9-16 days and followed by a 9-week follow-up period. Cells from peripheral blood were analysed by flow cytometry at every study visit before the IL-2 injections and one day after the 5th IL-2 injection. The primary objective was to show an increase in the percentage of CD25hi cells among CD3+CD4+Foxp3+CD127lo Treg cells by at least 100% (2-fold) after the 4th treatment cycle compared to baseline. Safety and tolerability were evaluated descriptively. Secondary objectives included the clinical responses assessed by SLEDAI and changes in serological and other immunological parameters.
Results: All 12 patients showed an effective and cycle-dependent increase in the percentage of CD25hi cells among Treg (p<0.001). 10 patients showed a reduction in SLEDAI (83.3%, p<0.05) and 8 patients achieved a clinical response (66.7%) with a complete disappearance of clinical manifestations such as rash, arthritis, myositis and alopecia. Levels of complement were significantly increased after the treatment compared to baseline (p<0.05). However, we could not observe a reduction in levels of anti-dsDNA-Abs. Treatment-related adverse events were generally mild and transient.
Conclusion: Low-dose IL-2 therapy is capable to safely and selectively expand the Treg population and to decrease disease activity in patients with active and refractory SLE. This study provides the basis for larger and placebo-controlled clincial studies aiming to prove the efficacy of this novel biologic treatment strategy.
Disclosure: J. Humrich, None; C. von Spee-Mayer, None; E. Siegert, None; A. Rose, None; M. Bertolo, None; P. Enghard, None; F. Hiepe, None; T. Alexander, None; E. Feist, None; A. Radbruch, None; G. R. Burmester, AbbVie, Bristol-Myers Squibb, MedImmune, Merck, Pfizer, Roche, and UCB, 2,AbbVie, Bristol-Myers Squibb, MedImmune, Merck, Pfizer, Roche, and UCB, 5,AbbVie, Bristol-Myers Squibb, Merck, Pfizer, Roche, and UCB, 8; G. Riemekasten, None.
To cite this abstract in AMA style:Humrich J, von Spee-Mayer C, Siegert E, Rose A, Bertolo M, Enghard P, Hiepe F, Alexander T, Feist E, Radbruch A, Burmester GR, Riemekasten G. Low-Dose IL-2 Therapy in Refractory SLE: Results from Single Center Phase I/IIa Clinical Trial [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). http://acrabstracts.org/abstract/low-dose-il-2-therapy-in-refractory-sle-results-from-single-center-phase-iiia-clinical-trial/. Accessed November 22, 2017.
« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - http://acrabstracts.org/abstract/low-dose-il-2-therapy-in-refractory-sle-results-from-single-center-phase-iiia-clinical-trial/